Posted on April 27th, 2012, 9:50 am
Pharmaceutical Business Review Pierre Fabre pharmaceutical division president Frederic Duchesne said, "These results confirm the relevance of our strategic choice to make neuropsychiatry a major focus of Pierre Fabre R&D." Levomilnacipran (1S, 2R-milnacipran), an enantiomer of ... |